EMDA for the Treatment of NMIBC

What is EMDA®

EMDA®, Electromotive Drug Administration, is a device-assisted therapy that increases drug transport across biological membranes under the influence of an electric field

EMDA® is characterized by a combination of different electromolecular interactions that improve drug absorption from 4 to 7 times:

Iontophoresis
Electrophoresis/Electroosmosis
Electroporation

The deeper drug penetration and the greater drug bioavailability result in an increased clinical effectiveness

Treatment Modality

Urogenic 16F electrode catheter is inserted into the bladder
The bladder is drained to remove residual electrolytes
The drug solution is administered
Two dispersive electrodes are placed on the sides of the navel with an abundant layer of conductive gel
A micro-current is applied for 20 minutes

EMDA® treatment is quick, easy to use and safe

WHY EMDA®

A unique technology to augment the effect of intravesical chemotherapy by creating an electric field across the bladder wall which increases urothelium’s permeability

The Physion EMDA® system has been proven excellent results in treating high-risk and intermediate-risk patients with non-muscle invasive bladder cancer.
EMDA® + Mitomycin treatment is an efficacy tool in the long-term conservative strategy of high-risk unresponsive to BCG as a “bladder sparing” therapy.
Several thousand treatment cycles have been performed with complete safety following TURBT: significantly reduced recurrence and progression with increased disease-free interval.
EMDA® can be used with all types of Mitomycin and in sequential treatment EMDA® + Mitomycin is combined with BCG.
More data on EMDA® now available than any other device-assisted drug delivery system available.
Proven deeper tissue penetration of Mytomicin with EMDA® compared to passive administration.
In according to EAU Guidelines 2021.

Electromotive drug administration

The efficacy of MMC using electromotive drug administration (EMDA) sequentially combined with BCG in

patients with high-risk tumours has been demonstrated in one small RCT [300]. The definitive conclusion,

however, needs further confirmation. For application of device-assisted instillations in patients recurring after

BCG treatment, see Section 7.9.3.

Bladder Cancer Protocols

Discover more about our extensive range of professional services. We constantly update this page, but if you still can’t find what you’re looking for, please feel free to get in touch with us – we will be more than happy to help.